BIOMUNEX PHARMACEUTICALS

If you want to know more about Biomunex bispecific antibody BiXAb® platform and MAIT engagers, a new immunotherapy approach: Let's talk at BIO Europe, Stockholm, Sweden! 🔬💪 Reach out our team in the Biopartnering system. 📍 November 4-6, 2024 #Biomunex #BIOEurope #BIOEurope2024 #Healthscience #BiXAb

At Biomunex, during Pink October in support of all women affected by breast cancer, and at any time, we are fully committed to development of innovative bispecific antibodies to fight against cancer. 👩 🎗 #PinkOctober #BreastCancer #Oncology #Biotech #Biomunex

At Biomunex, during Pink October in support of all women affected by breast cancer, and at any time, we are fully committed to development of innovative bispecific antibodies to fight against cancer. 👩 🎗 #PinkOctober #BreastCancer #Oncology #Biotech #Biomunex

Simon Plyte, CSO of Biomunex, will present Biomunex's BiXAb® MAIT Engagers at the Festival of Biologics 2024, to be held from October 15-17, in Basel, Switzerland. 🔍📊 ➡️ Meet him Tuesday, October 15 at 3:00 pm (CEST) A good opportunity to discover our BiXAb MAIT Engagers, our innovative technology, connecting & networking! #Biomunex #FestivalofBiologics #BiXAb #Healthscience

Biomunex presents new preclinical data on MAIT cell redirection approach at AACR 2024 meeting 🔬 ➡ Wednesday, April 10th, 2024, from 9.00 a.m. to 12:30 p.m ➡ San Diego Conference Centre, San Diego, California, USA #Biomunex #MAITengagers #AACR2024

Great to be here at the AACR in San Diego. 22,000 people focused on one thing...tackling cancer. Biomunex are contributing to this with an innovative approach to T-cell redirection: MAIT engagers. I will be presenting this at the Poster session on Wednesday morning.

Join Simon Plyte, CSO of Biomunex, at American Association for Cancer Research (AACR) 2024, at San Diego Convention Center, San Diego, CA, USA, and attend his poster presentation on MAIT engagers 🔬 ➡️ Poster No. 6708. ➡️ Poster session: Wednesday 10th April at 9.00 – 12.00 a.m. #Biomunex #AACR #AACR2024 #MAITengagers

Immunothérapie : une approche prometteuse basée sur une découverte de l’Institut Curie va être développée par Biomunex Partenaires depuis 2019, l’Institut Curie et BIOMUNEX PHARMACEUTICALS annoncent une nouvelle étape dans leur collaboration de recherche stratégique. Biomunex signe un accord de licence exclusif avec l’Institut Curie pour le développement clinique d’une nouvelle catégorie d’anticorps, capables de cibler, d’engager et de rediriger spécifiquement les cellules MAIT pour détruire les cellules cancéreuses. 👉 Un pas de plus vers de nouvelles immunothérapies de pointe, plus sûres et plus efficaces, au bénéfice des patients. Pour en savoir plus :

I'm delighted to attend BIO-Europe Spring, from March 18 to 20, 2024, in Barcelona, to meet colleagues and friends in the biopharma community. #Biomunex #BIOEurope #BIO2024

💭 “We are pleased to announce the signature of an exclusive license and exploitation agreement with Institut Curie, France's first and leading cancer research center, and a major historical partner of Biomunex, for the development of a new class of antibodies, the MAIT engagers. These MAIT engagers will be able to specifically target and engage MAIT cells to kill cancer cells”, said Dr. Pierre-Emmanuel Gerard, Founder and CEO of Biomunex. ➡ Biomunex, which was a 50% co-owner and the co-inventor of this unique innovative approach, now holds its full worldwide rights. Read the press release 🗞 https://lnkd.in/eiqDEpzB #Biomunex #MAITengagers #Immunotherapy